230 related articles for article (PubMed ID: 31849147)
21. Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.
von Witzleben A; Goerttler LT; Marienfeld R; Barth H; Lechel A; Mellert K; Böhm M; Kornmann M; Mayer-Steinacker R; von Baer A; Schultheiss M; Flanagan AM; Möller P; Brüderlein S; Barth TF
Cancer Res; 2015 Sep; 75(18):3823-31. PubMed ID: 26183925
[TBL] [Abstract][Full Text] [Related]
22. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
23. Palbociclib enhances the effect of doxorubicin-induced apoptosis in activated B-cell-like diffuse large B-cell lymphoma cells.
Yi L; Hu L; Huang K; Li Q; Wang Y; Wang J; Zhai Z
Anticancer Drugs; 2023 Feb; 34(2):257-268. PubMed ID: 36206105
[TBL] [Abstract][Full Text] [Related]
24. Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
Dowless M; Lowery CD; Shackleford T; Renschler M; Stephens J; Flack R; Blosser W; Gupta S; Stewart J; Webster Y; Dempsey J; VanWye AB; Ebert P; Iversen P; Olsen JB; Gong X; Buchanan S; Houghton P; Stancato L
Clin Cancer Res; 2018 Dec; 24(23):6028-6039. PubMed ID: 30131386
[TBL] [Abstract][Full Text] [Related]
25. The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels.
Nakatsukasa H; Takahashi M; Takahashi K; Takashima T; Asano Y; Morisaki T; Kashiwagi S; Noda S; Nakamura Y
Biol Pharm Bull; 2022; 45(10):1476-1481. PubMed ID: 36184505
[TBL] [Abstract][Full Text] [Related]
26. [Classification of aggressive B-cell lymphomas : News and open questions].
Rosenwald A; Menter T; Dirnhofer S
Pathologie (Heidelb); 2023 May; 44(3):166-172. PubMed ID: 36918411
[TBL] [Abstract][Full Text] [Related]
27. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Tamura K
Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
[TBL] [Abstract][Full Text] [Related]
28. Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.
de Jonge AV; Duetz C; Bruins WSC; Korst CLBM; Rentenaar R; Cosovic M; Eken M; Twickler I; Nijland M; van der Poel MWM; de Heer K; Klerk CPW; Strobbe L; Oosterveld M; Boersma R; Koene HR; Roemer MGM; van Werkhoven E; Chamuleau MED; Mutis T
Blood Adv; 2024 Mar; 8(5):1094-1104. PubMed ID: 38191686
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.
Al-Kawaaz M; Sanchez T; Kluk MJ
J Hematop; 2019 Jun; 12(2):57-65. PubMed ID: 31404445
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.
Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Arakawa F; Niino D; Ohshima K
Pathol Int; 2015 Oct; 65(10):519-27. PubMed ID: 26224092
[TBL] [Abstract][Full Text] [Related]
31. Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphoma.
Graef CM; Gödel P; Falderbaum P; Balke-Want H; Simon F; Sieg N; Naendrup JH; Neumann MA; Gillessen S; Bröckelmann PJ; Eichenauer DA; Borchmann P; von Tresckow B; Heger JM
Eur J Haematol; 2022 May; 108(5):403-412. PubMed ID: 35090068
[TBL] [Abstract][Full Text] [Related]
32. CDK4/6 blockade in breast cancer: current experience and future perspectives.
Zardavas D; Pondé N; Tryfonidis K
Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
[TBL] [Abstract][Full Text] [Related]
33. Advances in pathological understanding of high-grade B cell lymphomas.
Li S; Lin P; Medeiros LJ
Expert Rev Hematol; 2018 Aug; 11(8):637-648. PubMed ID: 29989509
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
[TBL] [Abstract][Full Text] [Related]
35. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
36. Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings.
Ott G
Br J Haematol; 2017 Sep; 178(6):871-887. PubMed ID: 28748558
[TBL] [Abstract][Full Text] [Related]
37. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
Wang W; Hu S; Lu X; Young KH; Medeiros LJ
Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
[TBL] [Abstract][Full Text] [Related]
38. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
[TBL] [Abstract][Full Text] [Related]
39. Can CDK4/6 inhibitors cause fatal lung injury?
Jazieh KA; Budd GT; Dalpiaz N; Abraham J
Expert Rev Anticancer Ther; 2019 Nov; 19(11):917-919. PubMed ID: 31566017
[No Abstract] [Full Text] [Related]
40. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]